What are the recommended treatment options for a transplant‑eligible patient with relapsed multiple myeloma after prior bortezomib, lenalidomide, and dexamethasone therapy?

Treatment of Relapsed Multiple Myeloma After Prior Bortezomib, Lenalidomide, and Dexamethasone

For transplant-eligible patients with relapsed multiple myeloma after prior bortezomib, lenalidomide, and dexamethasone, the optimal approach is daratumumab-based triplet therapy, with daratumumab/bortezomib/dexamethasone (DVd) being the preferred regimen based on superior real-world outcomes, or consideration of salvage autologous stem cell transplantation if progression-free survival after first transplant was ≥18 months. 1, 2

Primary Treatment Strategy

Daratumumab-Based Triplet Therapy

• Daratumumab/bortezomib/dexamethasone (DVd) demonstrates an 82% overall response rate with median progression-free survival of 16 months in real-world first relapse settings, with results remaining consistent regardless of prior lenalidomide exposure. 2

• The median time to next treatment with DVd is 20 months, with estimated 2-year overall survival of 74%, making this the most robust option for patients previously exposed to both bortezomib and lenalidomide. 2

• Weekly bortezomib dosing in the DVd regimen significantly reduces peripheral neuropathy risk to only 7% for grade 2-3 toxicity, addressing a major quality-of-life concern compared to twice-weekly dosing. 2

• Bortezomib retreatment is explicitly FDA-approved for patients who previously responded and relapsed at least 6 months after completing prior bortezomib treatment, starting at the last tolerated dose. 3

Alternative Triplet Regimens

• Carfilzomib/cyclophosphamide/dexamethasone is particularly effective in lenalidomide-refractory populations, showing progression-free survival of 18.4 months versus 11.3 months when cyclophosphamide is added to carfilzomib/dexamethasone in this subgroup. 1

• Elotuzumab/bortezomib/dexamethasone provides a 28% reduction in risk of disease progression or death compared to bortezomib/dexamethasone alone, with median progression-free survival of 9.7 versus 6.9 months. 1

• Pomalidomide/cyclophosphamide/dexamethasone represents a reasonable option for double-refractory cases (both bortezomib and lenalidomide refractory). 1

Salvage Autologous Stem Cell Transplantation

• Salvage ASCT should be offered to transplant-eligible patients if progression-free survival after first transplant was ≥18 months, as this population demonstrates meaningful benefit from repeat transplantation. 1

• For patients who deferred initial transplant, salvage ASCT at first relapse is administered to approximately 79% of eligible patients and does not appear to negatively impact overall survival compared to early transplant. 1

• Early transplant delays disease progression (median progression-free survival 50 versus 36 months) but without significant overall survival difference at 4 years (81% versus 82%), supporting flexibility in timing. 1

Risk Stratification and Treatment Modification

High-Risk Features Requiring Intensified Approach

• Patients with del(17p), high International Staging System stage, or extramedullary disease have significantly inferior outcomes with standard triplet therapy and should be prioritized for clinical trials or T-cell redirecting therapies. 1, 2

• Combined therapy with second-generation proteasome inhibitors and monoclonal antibodies demonstrates improved outcomes specifically in del(17p) populations compared to historical controls. 1

Early Relapse Considerations

• Patients progressing within 18 months of treatment initiation or within 12 months of autologous stem cell transplant have significantly worse outcomes and require more aggressive salvage strategies. 2

• Patients relapsing during therapy or within 1 year of completing therapy are considered less sensitive to previous agents and should not receive the same regimen. 1

• Conversely, patients relapsing more than 1 year after treatment completion will likely respond to repeat courses of previous therapy. 1

Treatment Selection Algorithm

For bortezomib/lenalidomide/dexamethasone-exposed patients:

1. If progression >12 months post-ASCT or >18 months from treatment start: Consider DVd with weekly bortezomib as first choice, or salvage ASCT if first transplant PFS ≥18 months. 1, 2

2. If lenalidomide-refractory (progression on lenalidomide maintenance): Prioritize carfilzomib/cyclophosphamide/dexamethasone or DVd. 1

3. If bortezomib-refractory: Consider daratumumab/lenalidomide/dexamethasone combinations (though this requires lenalidomide re-challenge). 1

4. If double-refractory (both bortezomib and lenalidomide): Use pomalidomide-based combinations with monoclonal antibodies or cyclophosphamide. 1

5. If high-risk cytogenetics or early relapse (<18 months): Prioritize clinical trials with T-cell redirecting therapies or novel quadruplet regimens over standard triplets. 1, 2, 4

Critical Caveats

• The NCCN guidelines classify these regimens as appropriate for relapsed/refractory disease after 1-3 prior therapies, confirming applicability to first relapse scenarios. 1

• Triplet combinations consistently outperform doublet regimens across all relapsed settings when tolerated, making them the standard approach. 1

• Dose modifications for bortezomib are essential: reduce from 1.3 mg/m² to 1 mg/m² to 0.7 mg/m² for grade 3+ toxicities or recurrent dose holds. 3

• At least 72 hours must elapse between consecutive bortezomib doses to minimize toxicity. 3